Pre-operative Sensitivity of DR-70 in Colorectal Cancer Patients

DR-70在大腸直腸癌病人的術前敏感度

顏珉玄(Min-Hsuan Yen) ； 張東晟(Tung-Cheng Chang) ； 梁金銅(Jin-Tung Liang)

《中華民國大腸直腸外科醫學會雜誌》 28卷4期 (2017/12) Pp. 171-176

https://doi.org/10.6312/SCRSTW.2017.28(4).10610

摘要

Purpose. This study investigates the pre-operative sensitivity of a novel tumor marker for colorectal cancer (CRC). Methods. Atotal of 83 patients with colorectal cancer from 2014 to 2016 were enrolled in this retrospective study. All patients received colectomy with at least D2 lymph node dissection. DR-70 and carcinoembryonic antigen (CEA) levels were tested and included in the preoperative evaluation. Hematological and biochemical tests, pathology, and demographic data from the patients were analyzed to evaluate the correlation of DR-70 and CEA with the distribution of colorectal cancer. Results. Among the 83 patients, there were 12 (14.4 %) patients in pathological stage IV, 39 (46.9%) in stage III, 14 (16.8%) in stage II, and 18 (21.9%) in stage I. The sensitivity of DR-70 (＞ 1 mg/L) and CEA (＞ 5 μg/L) were 18.8% and 3.13% for the 32 patients in the early stages of colorectal cancer (stages I and II; p value = 0.04), while they were 23.5% and 49.0% for the 51 patients in the late stages (stages III and IV), respectively (p value = 0.19). However, for each of the four pathological stages, the sensitivity was not statistically significant. There was no correlation between CEA and DR-70 (p value = 0.661). There was no statistical significance in regard to the TNM staging. The perineural invasion was the only clinical characteristic that affected the sensitivity of DR-70. Conclusions. The pre-operative sensitivity of DR70 in our patient with DR-70 was 21.7%, and there is no correlation between CEA and DR-70.

關鍵字

DR-70 ； CEA ； Colorectal cancer

並列摘要

目的：探討DR-70此大腸直腸癌篩檢工具對協助臨床診斷之適用性。方法：本研究採回溯性研究設計，在2014年至2016年間，共納入83位符合篩選標準之大腸直腸癌病患。此83位病患均接受至少有D2淋巴結廓清術的大腸直腸切除手術，並也在術前進行DR-70與CEA的檢測。將病患的血液與生化學檢查結果、病理報告和基本人口學資料納入統計分析，再評估與DR-70和CEA檢測數值之相關性。結果：83位大腸直腸癌病患中，第四期有12位(佔14.4%)，第三期有39位(佔46.9%)，第二期有14位(佔16.8%)及第一期有18位(佔21.9%)。32位的早期(第一、二期)大腸直腸癌病患其DR-70和CEA的敏感度分別是18.8%和3.13%(p value為0.04)；而51位晚期(第三、四期)病者的DR-70和CEA的敏感度分別為23.5%和49.0%(p value為0.19)；但以各別分期來看兩者的敏感度，均無統計顯著差異。而DR-70和CEA兩者的濃度值並無相關性。在TNM腫瘤分類，各別T、N及M的DR-70和CEA的敏感度也均無統計顯著差異。神經侵犯是唯一在臨床上會影響DR-70敏感度的因子。結論：在大腸直腸癌病人，DR-70的敏感度約為21.7%，而DR-70和CEA兩者無相關性。

並列關鍵字

DR-70 ； CEA ； 大腸直腸癌

參考文獻

8. Yesil A, Babacan Abanonu G, Colak Y, Paker N, Gonen C. Prognostic Significance of DR-70 Levels in Dysplastic Colorectal Polyps. Gastroenterology research and practice. 2013;2013:275392.

1. Pawa N, Arulampalam T, Norton JD. Screening for colorectal cancer: established and emerging modalities. Nature reviews. Gastroenterology & hepatology. 2011;8(12):711-722.

2. Su BB, Shi H, Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World journal of gastroenterology : WJG. 2012;18(17):2121-2126.

3. Wajsman Z, Williams PD, Greco J, Murphy GP. Further study of fibrinogen degradation products in bladder cancer detection. Urology. 1978;12(6):659-661.

4. Small-Howard AL, Harris H. Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients. Journal of immunoassay & immunochemistry. 2010;31(2):131-147.